While there is clinical benefit for combined anti-PD-1 blockade and chemotherapy for a subset of patients with early stage [1, 2] and metastatic triple negative breast cancer [3, 4], no such gains have been observed for most patients with HR+/HER2-negative breast cancer, particularly in the metastatic setting. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.